KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Gains from Investment Securities (2017 - 2026)

Amneal Pharmaceuticals has reported Gains from Investment Securities over the past 9 years, most recently at $4.7 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 287.85% year-over-year to $4.7 million; the TTM value through Dec 2025 reached $22.3 million, up 1562.77%, while the annual FY2025 figure was $22.3 million, 1562.77% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $4.7 million at Amneal Pharmaceuticals, up from -$4.3 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $23.1 million in Q2 2025 and troughed at -$6.8 million in Q2 2023.
  • A 5-year average of $1.6 million and a median of $274000.0 in 2023 define the central range for Gains from Investment Securities.
  • On a YoY basis, Gains from Investment Securities climbed as much as 492.0% in 2023 and fell as far as 2412.96% in 2023.
  • Year by year, Gains from Investment Securities stood at -$6.7 million in 2021, then soared by 260.11% to $10.7 million in 2022, then crashed by 97.43% to $274000.0 in 2023, then plummeted by 1013.5% to -$2.5 million in 2024, then surged by 287.85% to $4.7 million in 2025.
  • Business Quant data shows Gains from Investment Securities for AMRX at $4.7 million in Q4 2025, -$4.3 million in Q3 2025, and $23.1 million in Q2 2025.